Associate Director (m/f/d), Computational Pathology Biomarker Lead (Oncology/BioPharma)

Das ist der Job

Do you thrive at the intersection of AI innovation and clinical translation?

Darum lohnt es sich

Do you have expertise in, and a passion for leading cross functional teams to drive innovation? In this position you will work with a multi-disciplinary team to pioneer AI-enabled computational pathology and multi-modal biomarkers that fundamentally change how we approach patient selection and drug development, aiming to improve clinical outcomes.

Our team operates in a demanding, fast-paced environment where excellent collaboration, clear communication and precise organization are critical. Would you like to apply your expertise to impact the Oncology and/or BioPharma strategic vision in a company that follows the science and turns ideas into life changing medicines?

Then AstraZeneca might be the one for you! You will have the opportunity to impact an industry-leading portfolio of targeted therapy programs from inception through to life cycle management for marketed drugs.

ABOUT ASTRAZENECA AstraZeneca is a global, science-led, patient-focused biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines for some of the world's most serious diseases. But we're more than one of the world's leading pharmaceutical companies.

SITE DESCRIPTION - Munich, Germany At Computational Pathology Munich (CPM), we make a significant contribution to high-performance, data-driven research and development.

BUSINESS AREA AstraZeneca's Enterprise AI organization is building the future of drug development, a fully integrated AI engine that connects data, technology, and expertise to accelerate breakthroughs across our portfolio.

Within AI for Computational Pathology and Biomarkers, we're pioneering AI-powered solutions that transform patient selection, biomarker development, and clinical decision-making at enterprise scale.

We thrive on collaboration: actively leveraging capabilities across the organization, promoting reuse, and scaling innovations from concept to global impact. Our measure of success isn't just innovation-it's adoption, scale, and tangible results across therapeutic areas and geographies.